<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200301046656N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-01-21</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>Anesthetic Efficacy of Modified Infiltration Technique in mandibular molars</public_title>
      <acronym></acronym>
      <scientific_title>Primary and Supplementary Anesthetic Efficacy of Modified Infiltration Technique with 4% Articaine versus Inferior Alveolar Nerve Block with 2% lidocaine  in Mandibular molars with Irreversible Pulpitis: A Randomized Clinical Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-01-31</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>84</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/53111</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The randomization table will be provided by the statistician. The permuted block randomization method will be used for randomizing the participants. In each block, randomization sequences will be generated using Microsoft Excel software. The statistician will be blinded to the study's aims and methods of injections, Blinding description: The investigator will leave the treatment room after evaluating the inclusion and exclusion criteria. Then, the practitioner will carry out the injection after opening the allocated opaque and sealed envelope just before the injection. afterward, the practitioner will use a rubber dam to blind the investigator and tell the investigator to come back to the treatment room and collect the required information. The code on the envelopes, that distinguishes the type of injection using the randomization sequence, will be recorded in the patients' profiles. The investigator will be blinded to the type of injection. Due to the different methods of the two injections, completely blinding the practitioner and patients will not be applicable. The statistician will be blinded to the aims and steps of the present study.</study_design>
      <phase>3</phase>
      <hc_freetext>Irreversible pulpitis.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Subperiosteal group. In this group, patients will receive an anesthetic subperiosteal injection of 1.8 mL articaine 4% with 1:100.000 epinephrine with an extra short 27-gauge needle. This injection will be carried out in both the mesial and distal parts. Intervention 2: Control group: Inferior alveolar nerve block group. In this group, patients will receive an inferior alveolar nerve block with 1.8 mL lidocaine 2% with 1:100.000 epinephrine using a long 27-gauge needle. Intervention 3: Supplementary modified infiltration technique group: in this group, patients will receive an Inferior alveolar nerve block anesthesia, and after the numbness of the lower lip, they will receive a subperiosteal injection of 1.8 mL 4% articaine with 1:100.000 epinephrine, with a 27-gauge, extra short needle.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Nazanin Zargar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Dental school, Shahid Beheshti University of Medical Sciences, Daneshjou Blvd., Evin Ave, Shahid Chamran Highway, Tehran, Iran.</address>
        <city>tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1983963113</zip>
        <telephone>+98 21 2217 5350</telephone>
        <email>nzargar48@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Nazanin Zargar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Dental school, Shahid Beheshti University of Medical Sciences, Daneshjou Blvd., Evin Ave, Shahid Chamran Highway, Tehran, Iran.</address>
        <city>tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1983963113</zip>
        <telephone>+98 21 2217 5350</telephone>
        <email>nzargar48@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>having a first/second mandibular molar tooth diagnosed with irreversible pulpitis
absence of any systemic disease
absence pregnancy or nursing for female participants
occurrence of periapical lesion on preoperative radiograph(s)
absence of any inflammation or lesion/wound in anesthetic injection's area
absence of a history of any allergic reaction to the materials used in the present study</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>more than 0.5 mm mobility on occluso-gingival and/or bucco-lingual and/or mesio-distal direction.
taking analgesic medications less than a day before the beginning of the treatment
absence of vital pulpal tissue upon access cavity preparation</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K04.02</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Irreversible pulpitis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Subperiosteal group. In this group, patients will receive an anesthetic subperiosteal injection of 1.8 mL articaine 4% with 1:100.000 epinephrine with an extra short 27-gauge needle. This injection will be carried out in both the mesial and distal parts.</i_keyword>
      <i_keyword>Control group: Inferior alveolar nerve block group. In this group, patients will receive an inferior alveolar nerve block with 1.8 mL lidocaine 2% with 1:100.000 epinephrine using a long 27-gauge needle.</i_keyword>
      <i_keyword>Supplementary modified infiltration technique group: in this group, patients will receive an Inferior alveolar nerve block anesthesia, and after the numbness of the lower lip, they will receive a subperiosteal injection of 1.8 mL 4% articaine with 1:100.000 epinephrine, with a 27-gauge, extra short needle.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Patient's perceived pain score. Timepoint: before the injection, while injecting, access cavity preparation, and initial filing. Method of measurement: 170 mm Heft Parker Visual anlogue scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-01-28</approval_date>
        <contact_name>the Ethics Committee of Shahid Beheshti University of Medical Sciences</contact_name>
        <contact_address>the Ethics Committee of Shahid Beheshti University of Medical Sciences, Evin, Tehran. tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
